Amylyx Pharmaceuticals (AMLX) Net Cash Flow (2021 - 2026)

Amylyx Pharmaceuticals' Net Cash Flow history runs 6 years deep, the most recent figure standing at $2.6 million for Q1 2026.

• On a quarterly basis, Net Cash Flow rose 114.57% year-over-year to $2.6 million in Q1 2026; TTM through Mar 2026 was $168.1 million, a 252.96% increase from a year earlier, with the FY2025 full-year figure at $147.7 million, up 261.19% from the prior year.
• Net Cash Flow rose to $2.6 million in Q1 2026 per AMLX's latest filing, from $1.4 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $166.5 million in Q3 2025 and bottomed at -$112.4 million in Q3 2023.
• The 5-year median for Net Cash Flow is $1.4 million (2025), against an average of $10.5 million.
• Biggest YoY gain for Net Cash Flow was 6325.65% in 2025; the steepest drop was 3965.73% in 2025.
• Year by year, Net Cash Flow stood at -$45.7 million in 2022, then surged by 175.92% to $34.7 million in 2023, then slumped by 82.48% to $6.1 million in 2024, then sank by 77.69% to $1.4 million in 2025, then soared by 91.38% to $2.6 million in 2026.
• Per Business Quant, the three latest AMLX Net Cash Flow figures stand at $2.6 million (Q1 2026), $1.4 million (Q4 2025), and $166.5 million (Q3 2025).